While acute myeloid leukemia (AML) is still associated with a low cure rate, recent advances in understanding its molecular complexity have significantly improved therapy for subgroups of patients, including those harboring FLT3, IDH1, or IDH2 mutations [1]. This evidence concerns the gene FLT3 and acute myeloid leukemia.